Combinib 250mg (Lapatinib Tablet) 250mg

Combinib 250mg (Lapatinib) is an oral tablet used alongside other treatments for certain types of advanced breast cancer. This targeted therapy helps slow cancer progression by blocking specific growth signals. Always consult a healthcare provider before use. Suitable for adults with HER2-positive tumors.

Strength

250mg

Manufacturer / TM Owner

CIPLA LTD

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Combinib 250mg is prescribed for adults with HER2-positive metastatic breast cancer, often combined with other medications like capecitabine or trastuzumab. It may also be used in other cancer types as directed by an oncologist. This drug works by targeting proteins that promote cancer cell growth. Always follow a doctor’s guidance for proper use.

Side Effects

Many patients experience mild to moderate side effects such as nausea, diarrhea, or fatigue. Some may notice changes in skin or hair texture. These effects vary by individual and are typically temporary. Staying hydrated and following dietary advice can help manage discomfort.

Precautions & Warnings

Keep Combinib 250mg in a cool, dry place away from direct sunlight. Store securely out of reach of children and pets. Do not use if the packaging is damaged or expired. Inform your doctor about all current medications and health conditions before starting this treatment.

Avoid Interactions

Combinib 250mg may interact with strong CYP3A4 inhibitors like ketoconazole or grapefruit juice, which can increase drug levels. Avoid alcohol and herbal supplements unless approved by a healthcare provider. Certain heart medications and antibiotics may also affect how this drug works.

Frequently Asked Questions

Combinib 250mg is used to treat HER2-positive metastatic breast cancer in adults, often in combination with other therapies.

Take Combinib 250mg exactly as prescribed by your doctor, usually once or twice daily with or without food.

Common side effects include diarrhea, nausea, fatigue, and skin changes. Most are mild and temporary.

Avoid grapefruit juice as it may increase the drug’s levels in your body, leading to stronger effects.

This medication may harm an unborn baby. Use effective birth control and discuss risks with your doctor before starting treatment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.